BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang TW, Rhim H, Lee J, Song KD, Lee MW, Kim YS, Lim HK, Jang KM, Kim SH, Gwak GY, Jung SH. Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. Eur Radiol 2016;26:3437-46. [PMID: 26747262 DOI: 10.1007/s00330-015-4190-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu Z, Yu N, Wang H, Li S, Yan J, Zhang G. Pre-radiofrequency ablation MRI imaging features predict the local tumor progression in hepatocellular carcinoma. Medicine (Baltimore). 2020;99:e23924. [PMID: 33350797 DOI: 10.1097/md.0000000000023924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhao Q, Xie L, Chen S, Xu X, Jiang T, Zheng S. Virtual navigation-guided radiofrequency ablation for recurrent hepatocellular carcinoma invisible on ultrasound after hepatic resection. Hepatobiliary & Pancreatic Diseases International 2020;19:532-40. [DOI: 10.1016/j.hbpd.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol. 2018; Epub ahead of print. [PMID: 30043160 DOI: 10.1007/s00330-018-5617-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features. Liver Cancer 2019;8:24-40. [PMID: 30815393 DOI: 10.1159/000488540] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
5 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
6 Cha DI, Kang TW, Jang KM, Kim YK, Kim SH, Ha SY, Sohn I. Hepatic neuroendocrine tumors: gadoxetic acid-enhanced magnetic resonance imaging findings with an emphasis on differentiation between primary and secondary tumors. Abdom Radiol (NY) 2018;43:3331-9. [PMID: 29858937 DOI: 10.1007/s00261-018-1653-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T. Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. Cancers (Basel) 2021;13:1460. [PMID: 33806751 DOI: 10.3390/cancers13061460] [Reference Citation Analysis]
8 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M. Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. Eur Radiol. 2018;28:1986-1993. [PMID: 29196855 DOI: 10.1007/s00330-017-5162-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
10 Hwang JA, Kang TW, Cha DI, Kim SH, Ha SY, Kim SW. Differentiation of Hepatic Sclerosed Hemangiomas From Cavernous Hemangiomas Based on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features. J Comput Assist Tomogr 2019;43:762-9. [PMID: 31356526 DOI: 10.1097/RCT.0000000000000905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
11 Lee S, Kang TW, Song KD, Lee MW, Rhim H, Lim HK, Kim SY, Sinn DH, Kim JM, Kim K, Ha SY. Effect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablation. Ann Surg. 2019;Online ahead of print. [PMID: 31058694 DOI: 10.1097/sla.0000000000003268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
12 Hwang JA, Kang TW, Kim YK, Kim SH, Paik YH, Ha SY, Kim S. Association between non-hypervascular hypointense nodules on gadoxetic acid-enhanced MRI and liver stiffness or hepatocellular carcinoma. European Journal of Radiology 2017;95:362-9. [DOI: 10.1016/j.ejrad.2017.08.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Kumar G, Goldberg SN, Wang Y, Velez E, Gourevitch S, Galun E, Ahmed M. Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition. Eur Radiol 2017;27:1238-47. [DOI: 10.1007/s00330-016-4405-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
14 Cho JY, Choi MS, Lee GS, Sohn W, Ahn J, Sinn DH, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clin Mol Hepatol 2016;22:477-86. [PMID: 28081587 DOI: 10.3350/cmh.2016.0048] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
15 Min JH, Kang TW, Kim YK, Kim SH, Shin KS, Lee JE, Ha SY, Sohn I. Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival. Eur Radiol 2018;28:2561-71. [PMID: 29368162 DOI: 10.1007/s00330-017-5248-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Min JH, Kang TW, Cha DI, Kim SH, Shin KS, Lee JE, Jang K, Ahn SH. Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer. Eur Radiol 2019;29:411-21. [DOI: 10.1007/s00330-018-5602-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 An C, Kim MJ. Imaging features related with prognosis of hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:509-16. [PMID: 30171295 DOI: 10.1007/s00261-018-1758-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]